In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction


Autoři: Sandra Silva-Arrieta aff001;  Philip J. R. Goulder aff002;  Christian Brander aff001
Působiště autorů: IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain aff001;  Department of Paediatrics, University of Oxford, Oxford, United Kingdom aff002;  HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa aff003;  Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, United States of America aff004;  University of Vic–Central University of Catalonia, Catalonia, Vic, Spain aff005;  Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain aff006
Vyšlo v časopise: In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction. PLoS Pathog 16(6): e32767. doi:10.1371/journal.ppat.1008607
Kategorie: Opinion
doi: https://doi.org/10.1371/journal.ppat.1008607


Zdroje

1. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991;351(6324):290–6.

2. Gotch F, Rothbard J, Howland K, Townsend A, McMichael A. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature. 1987;326(6116):881–2.

3. Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides Nature. 1988;336(6198):484–7.

4. Brander C, Walker BD. The HLA-class I restricted CTL response in HIV-1 infection: Identification of optimal epitopes. In: Korber B, Brander C, Walker BD, Koup R, Moore J, Haynes B, Myers G, editors. HIV Molecular Immunology Database 1995. Los Alamos, NM: Los Alamos National Laboratory: Theoretical Biology and Biophysics; 1995. p. 1–9.

5. Llano A, Cedeño S, Silva-Arrieta S, Brander C. The 2019 Optimal HIV CTL epitopes update: Growing diversity in epitope length and HLA restriction. In: Yusim K, Korber BTM, Brander C, Barouch D, de Boer R, Haynes BF, Koup R, Moore JP, Walker BD, Watkins DI, editors. HIV Molecular Immunology 2018. Los Alamos, NM: Los Alamos National Laboratory, Theoretical Biology and Biophysics; 2019. p. 3–27.

6. Burrows SR, Rossjohn J, McCluskey J. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol. 2006;27:11–6.

7. Yaciuk JC, Skaley M, Bardet W, Schafer F, Mojsilovic D, Cate S, et al. Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells. J Virol. 2014;88(22):12992–3004. doi: 10.1128/JVI.01914-14 25165114

8. Goulder PJ, Tang Y, Pelton SI, Walker BD. HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other. J Virol. 2000;74(11):5291–9.

9. de Campos-Lima PO, Gavioli R, Zhang QJ, Wallace LE, Dolcetti R, Rowe M, et al. HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A111 population. Science. 1993;260:98–100.

10. Gutiérrez MI, Spangler G, Kingma D, Raffeld M, Guerrero I, Misad O, et al. Epstein-Barr virus in nasal lymphomas contains multiple ongoing mutations in the EBNA-1 gene. Blood. 1998;92(2):600–6.

11. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 2008;9:1. doi: 10.1186/1471-2172-9-1 18211710

12. Frahm N, Yusim K, Suscovich TJ, Adams S, Sidney J, Hraber P, et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol. 2007;37(9):2419–33

13. Walters LC, Harlos K, Brackenridge S, Rozbesky D, Barrett JR, Jain V, et al. Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nat Commun. 2018;9(1):3137. doi: 10.1038/s41467-018-05459-z 30087334

14. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. 2020;130(5)2620–2629. doi: 10.1172/JCI137244 Epub 2020 Mar 27. 32217835

15. Friberg H, Beaumier CM, Park S, Pazoles P, Endy TP, Mathew A, et al. Protective versus pathologic pre-exposure cytokine profiles in dengue virus infection. PLoS Negl Trop Dis. 2018;12(12):e0006975. doi: 10.1371/journal.pntd.0006975 eCollection 2018 Dec. 30557313

16. Ruiz-Riol M, Llano A, Ibarrondo J, Zamarreño J, Yusim K, Bach V, et al. Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected. J Infect Dis. 2015;211(6):936–46. doi: 10.1093/infdis/jiu534 Epub 2014 Sep 23. 25249264


Článek vyšel v časopise

PLOS Pathogens


2020 Číslo 6
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Důležitost adherence při depresivním onemocnění
nový kurz
Autoři: MUDr. Eliška Bartečková, Ph.D.

Koncepce osteologické péče pro gynekology a praktické lékaře
Autoři: MUDr. František Šenk

Sekvenční léčba schizofrenie
Autoři: MUDr. Jana Hořínková, Ph.D.

Hypertenze a hypercholesterolémie – synergický efekt léčby
Autoři: prof. MUDr. Hana Rosolová, DrSc.

Multidisciplinární zkušenosti u pacientů s diabetem
Autoři: Prof. MUDr. Martin Haluzík, DrSc., prof. MUDr. Vojtěch Melenovský, CSc., prof. MUDr. Vladimír Tesař, DrSc.

Všechny kurzy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se